Liver function and cough drug: a safety check
NCT ID NCT06222892
First seen Jan 09, 2026 · Last updated May 09, 2026 · Updated 16 times
Summary
This study looked at how the drug camlipixant, being tested for chronic cough, behaves in people with liver impairment compared to those with healthy livers. It involved 32 adults aged 18-75. The goal was to understand safety and drug levels, not to treat the cough itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COUGH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Miami, Florida, 33136, United States
-
GSK Investigational Site
Orlando, Florida, 32809, United States
-
GSK Investigational Site
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.